KR101353140B1 - 금속 결합 화합물 및 그의 용도 - Google Patents

금속 결합 화합물 및 그의 용도 Download PDF

Info

Publication number
KR101353140B1
KR101353140B1 KR1020117031646A KR20117031646A KR101353140B1 KR 101353140 B1 KR101353140 B1 KR 101353140B1 KR 1020117031646 A KR1020117031646 A KR 1020117031646A KR 20117031646 A KR20117031646 A KR 20117031646A KR 101353140 B1 KR101353140 B1 KR 101353140B1
Authority
KR
South Korea
Prior art keywords
delete delete
lys
ala
peptide
tetrapeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117031646A
Other languages
English (en)
Korean (ko)
Other versions
KR20120023147A (ko
Inventor
데이비드 바로어
씨. 제랄드 커티스
에드워드 라우
나가라자 케이. 알. 라오
제임스 브이 윈클러
완넬 엠. 크룩
Original Assignee
디엠아이 바이오사이언시스, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26854102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101353140(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 디엠아이 바이오사이언시스, 인크 filed Critical 디엠아이 바이오사이언시스, 인크
Publication of KR20120023147A publication Critical patent/KR20120023147A/ko
Application granted granted Critical
Publication of KR101353140B1 publication Critical patent/KR101353140B1/ko
Assigned to 앰피오 파마슈티컬스 인코퍼레이티드 reassignment 앰피오 파마슈티컬스 인코퍼레이티드 권리의 전부이전등록 Assignors: 디엠아이 바이오사이언시스, 인크
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020117031646A 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도 Expired - Fee Related KR101353140B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15740499P 1999-10-01 1999-10-01
US60/157,404 1999-10-01
US21107800P 2000-06-13 2000-06-13
US60/211,078 2000-06-13
PCT/US2000/026952 WO2001025265A1 (en) 1999-10-01 2000-09-29 Metal-binding compounds and uses therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117006608A Division KR20110049875A (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20120023147A KR20120023147A (ko) 2012-03-12
KR101353140B1 true KR101353140B1 (ko) 2014-01-20

Family

ID=26854102

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020117031646A Expired - Fee Related KR101353140B1 (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020027004228A Ceased KR20020057966A (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020117006608A Ceased KR20110049875A (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020097012559A Expired - Fee Related KR101062041B1 (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020107008232A Ceased KR20100075503A (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020117031645A Expired - Fee Related KR101312880B1 (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020027004228A Ceased KR20020057966A (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020117006608A Ceased KR20110049875A (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020097012559A Expired - Fee Related KR101062041B1 (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020107008232A Ceased KR20100075503A (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도
KR1020117031645A Expired - Fee Related KR101312880B1 (ko) 1999-10-01 2000-09-29 금속 결합 화합물 및 그의 용도

Country Status (11)

Country Link
EP (2) EP2327713A1 (https=)
JP (1) JP5349722B2 (https=)
KR (6) KR101353140B1 (https=)
CN (2) CN1390231A (https=)
AT (1) ATE553116T1 (https=)
AU (1) AU770999C (https=)
BR (1) BR0014389A (https=)
CA (1) CA2385551A1 (https=)
IL (4) IL148797A0 (https=)
NZ (1) NZ518266A (https=)
WO (1) WO2001025265A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160417A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
US20030040602A1 (en) * 2001-04-30 2003-02-27 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1406 daltons
WO2003043518A2 (en) * 2001-11-20 2003-05-30 Dmi Biosciences, Inc. Methods and products for oral care
BR0315942A (pt) 2002-11-27 2005-10-04 Dmi Biosciences Inc Tratamento de doenças e condições mediadas pelo aumento de fosforilação
CN102088991A (zh) 2008-05-13 2011-06-08 堪萨斯大学 金属提取肽标签和相关方法
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
CN111909238B (zh) * 2017-06-29 2022-04-08 安徽省农业科学院农产品加工研究所 一种含有Ser-Cys的高锌螯合活性锌螯合肽及其应用
CA3204594A1 (en) * 2020-12-15 2022-06-23 Life Technologies Corporation Chemically defined serum albumin substitutes
CN113563418B (zh) * 2021-06-22 2023-03-03 中国科学院化学研究所 一种原位响应ros的人工酶及其制备方法与应用
CN114437175B (zh) * 2022-01-29 2023-09-29 山东第一医科大学第三附属医院(山东省医学科学院附属医院) 一种肽探针及其应用和包含该肽探针的试剂盒

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4022888A (en) 1975-09-09 1977-05-10 Diagnostic Data, Inc. Esterified orgotein
US4461724A (en) 1981-10-28 1984-07-24 Nippon Zoki Pharmaceutical Co., Ltd. Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them
US4912118A (en) 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
US4760051A (en) 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
US4877770A (en) 1985-02-08 1989-10-31 Procyte Corporation Chemical derivatives of GHL-Cu
US4767753A (en) 1985-02-08 1988-08-30 Procyte Corporation Methods and compositions for preventing ulcers
US4810693A (en) 1985-02-08 1989-03-07 Procyte Corporation Method for inducing biological coverings in wounds
US5550183A (en) 1985-02-08 1996-08-27 Procyte Corporation Metal-peptide compositions and methods for stimulating hair growth
US5348943A (en) 1985-02-08 1994-09-20 Procyte Corporation Cosmetic and skin treatment compositions
US5177061A (en) 1985-02-08 1993-01-05 Procyte Corporation Method for stimulating hair growth using GHL-Cu complexes
US4665054A (en) 1985-02-08 1987-05-12 Bioheal, Inc. Chemical derivatives of GHL-Cu
US5214032A (en) 1985-02-08 1993-05-25 Procyte Corporation GHL-CU pharmaceutical compositions and compounds
US5120831A (en) 1985-02-08 1992-06-09 Procyte Corporation Metal-peptide compositions
US5422096A (en) 1985-05-08 1995-06-06 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
JPS62116565A (ja) * 1985-11-15 1987-05-28 Fujisawa Pharmaceut Co Ltd 新規ペプチド
GB8603537D0 (en) 1986-02-13 1986-03-19 Parker D Conjugate compound
DE3851203T2 (de) 1987-05-11 1994-12-15 Procyte Corp Gebrauch von GHL-Cu Derivaten für die Herstellung eines Medikaments zur Stimulierung des Haarwachstums.
DE68917946T2 (de) 1988-01-29 1995-01-05 Peter H Proctor Haarwachstumanregung mit Nitroxyd und anderen Radikalen.
US5101041A (en) 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
US5759515A (en) 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5023237A (en) 1989-08-30 1991-06-11 Procyte Corporation Methods and compositions for healing ulcers
US5145838A (en) 1989-08-30 1992-09-08 Procyte Corporation Methods and compositions for healing ulcers
US5059588A (en) 1989-10-13 1991-10-22 Procyte Corporation, Incorporated Methods and compositions for healing bone using gly his lys: copper
US5118665A (en) 1990-02-09 1992-06-02 Procyte Corporation Anti-oxidative and anti-inflammatory metal:peptide complexes and uses thereof
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5252559A (en) 1991-08-20 1993-10-12 The Procter & Gamble Company His-Gly-Gly peptide and derivatives thereof for hair growth
US5280038A (en) 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
CA2094785A1 (en) 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
US5807535A (en) 1992-07-31 1998-09-15 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
US5380747A (en) 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5464934A (en) 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5476939A (en) 1993-12-30 1995-12-19 Abbott Laboratories Certain pyridyl and isoquinolyl carbinolamine derivatives
JPH07316192A (ja) 1994-05-27 1995-12-05 Hoechst Japan Ltd Ｌ−リシル−グリシル−ｌ−ヒスチジンおよびこれを含有する創傷治療剤
US5538945A (en) * 1994-06-17 1996-07-23 Procyte Corporation Stimulation of hair growth by peptide copper complexes
US5891418A (en) 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
JP3356289B2 (ja) 1995-06-26 2002-12-16 コンキャット リミティド 第一遷移系列元素に対してキレート化親和性および選択性のある化合物とその医療および診断への使用
US5637311A (en) 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US5786335A (en) 1995-11-06 1998-07-28 Warner-Lambert Company Sulfhydryl containing peptides for treating vascular disease
US5928955A (en) 1996-03-22 1999-07-27 California Institute Of Technology Peptidyl fluorescent chemosensor for divalent zinc
AR007200A1 (es) 1996-05-21 1999-10-13 Novartis Ag Derivados de acido n,n'-di(2-hidroxibencil)etilendiamina-n,n'-diacetico, su aplicacion, su empleo, procedimiento para elaborarlos y preparacionesfarmaceuticas que contienen a dichos derivados.
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
PL184070B1 (pl) 1996-07-30 2002-08-30 Politechnika Lodzka Sposób wytwarzania peptydów zawierających a-hydroksymetyloserynę
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
US5739395A (en) 1997-01-10 1998-04-14 University Of Florida Research Foundation, Inc. Method for synthesis of rhizoferrin
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
AU752383B2 (en) 1998-02-04 2002-09-19 University Of Florida Research Foundation, Inc. Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy
DE19819843A1 (de) 1998-05-05 1999-11-11 Biotechnolog Forschung Gmbh Metallchelat bindende Peptide
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Acc. Chem. Res. Vol.30:123-130(1997) *
Accounts of Chemical Research. 30(3), pp. 123-130, (1997) *
The Journal of Immunology. vol. 161, pp. 1829-1836, (1998) *

Also Published As

Publication number Publication date
EP2327713A1 (en) 2011-06-01
KR20090086437A (ko) 2009-08-12
IL148797A0 (en) 2002-09-12
CN102038932A (zh) 2011-05-04
AU770999B2 (en) 2004-03-11
WO2001025265A1 (en) 2001-04-12
EP1220870A1 (en) 2002-07-10
KR101062041B1 (ko) 2011-09-02
KR20120023147A (ko) 2012-03-12
KR20120024890A (ko) 2012-03-14
EP1220870A4 (en) 2004-04-07
KR20020057966A (ko) 2002-07-12
CN1390231A (zh) 2003-01-08
KR20110049875A (ko) 2011-05-12
KR20100075503A (ko) 2010-07-02
NZ518266A (en) 2005-01-28
AU770999C (en) 2005-04-21
HK1157635A1 (en) 2012-07-06
CN102038932B (zh) 2013-11-06
JP2003528814A (ja) 2003-09-30
EP1220870B1 (en) 2012-04-11
KR101312880B1 (ko) 2013-09-30
JP5349722B2 (ja) 2013-11-20
BR0014389A (pt) 2002-10-29
ATE553116T1 (de) 2012-04-15
IL202812A0 (en) 2011-07-31
IL207923A0 (en) 2011-07-31
CA2385551A1 (en) 2001-04-12
AU7740700A (en) 2001-05-10
IL148797A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
US8017728B2 (en) Metal-binding compounds and uses therefor
US7973008B2 (en) Metal-binding compounds and uses therefor
US6310041B1 (en) Synthetic complementary peptides and ophthalmologic uses thereof
US20030130185A1 (en) Metal-binding compounds and uses therefor
KR101353140B1 (ko) 금속 결합 화합물 및 그의 용도
US20030055003A1 (en) Use of copper chelators to inhibit the inactivation of protein C
WO2002064620A2 (en) Metal-binding compounds and uses therefor
HK1158230A (en) Metal-binding compounds and uses therefor
HK1157635B (en) Metal-binding compounds and uses thereof
WO2007135781A1 (ja) エフリンｂ２の活性を高めるペプチド，その塩，医薬用組成物，治療用キット
EP1152011A1 (en) Peptides inhibiting vascular endothelial cell migration
HK1051049A (en) Metal-binding compounds and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

FPAY Annual fee payment
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20170114

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170114

St.27 status event code: N-4-6-H10-H13-oth-PC1903